Source: Annual Congress 2005 - COPD - pathogenesis II
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
B. Alcazar, C. M Carrasco, M. M Ceres, N. Q Ruiz Rico, S. Merlos, F. G Vargas (Granada, Spain). Clinical and microbiological characteristics of Pseudomonas aeruginosa isolates from patients with COPD. Eur Respir J 2005; 26: Suppl. 49, 477

Member's Comments

No comment yet.

Related content which might interest you: The clinical evaluation of patients with Pseudomonas aeruginosa detected in respiratory specimens Source: Annual Congress 2012 - Management of pneumonia due to hospital pathogens Year: 2012 Acinetobacter baumani and Pseudomonas aeruginosa drug susceptibility after bacteriological analysis of sputum in patients mechanically ventilated in ICU Source: Eur Respir J 2003; 22: Suppl. 45, 450s Year: 2003 Clinical  profile  and outcome of patients with sputum positive Acinetobacter baumanni infection Source: International Congress 2018 – Difficult-to-treat respiratory infections Year: 2018 Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD. Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020 Pseudomonas aeruginosa colonisation in patients without bronchiectasis Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014 The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis Source: Eur Respir J, 51 (2) 1701953; 10.1183/13993003.01953-2017 Year: 2018 Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia pneumonia: 10 years experience of single center Source: International Congress 2019 – Airway infection in COPD Year: 2019 Antibiotic sensitivity of pseudomonas aeroginosa isolates of respiratory secretions taken from ICU patients of the NRITLD Source: Eur Respir J 2004; 24: Suppl. 48, 641s Year: 2004 Risk factors and outcomes of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa: a clinical case-control study Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017 Pseudomonas aeruginosa colonisation in bronchiectatic patients and clinical reflections Source: Eur Respir J 2006; 28: Suppl. 50, 61s Year: 2006 The clinical impact of Pseudomonas aeruginosa eradication in bronchiectasis in a Dutch referral centre Source: Eur Respir J, 53 (4) 1802081; 10.1183/13993003.02081-2018 Year: 2019 Pseudomonas aeruginosa drug susceptibility in patients hospitalized with COPD exacerbation and bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 541s Year: 2001 Clinical outcomes of tigecycline in the treatment of critically ill patients with multidrug-resistant Acinetobactor baumannii infection Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors Source: Eur Respir J 2010; 35: 598-615 Year: 2010 Does Pseudomonas aeruginosa infection alter sputum viscoelastic properties in bronchiectasis patients? Source: International Congress 2018 – Chronic respiratory disease: respiratory muscle function, breathing exercises and airway clearance techniques Year: 2018 Newly acquired pseudomonas aeruginosa in Belgian cystic fibrosis-patients: does the patients‘ P. aeruginosa genotype correlate with environmental genotypes? Source: Eur Respir J 2006; 28: Suppl. 50, 485s Year: 2006 Association of acinetobacter baumannii respiratory isolates with hospital outcomes in ventilated patients Source: Eur Respir J 2006; 28: Suppl. 50, 785s Year: 2006 Antibodies against Pseudomonas aeruginosa in patients with cystic fibrosis – clinical application Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research Year: 2018 Novel Pseudomonas aeruginosa scoring system to guide empiric anti-pseudomonal therapy in COPD patients with community-acquired pneumònia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 Molecular genetic characteristics of Pseudomonas aeruginosa strains isolated from children with cystic fibrosis in Moscow. Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021